Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513199 | 0.94 | APP (0.37) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL4526585 | 0.92 | APP (0.35) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL20553573 | 0.87 | APP (0.44) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL12878941 | 0.87 | APP (0.44) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL421993 | 0.84 | APP (0.50) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL25299218 | 0.82 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL20875302 | 0.82 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL19640302 | 0.82 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL22160261 | 0.82 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM | |
| SCHEMBL4731267 | 0.82 | APP (0.48) | APPLMNASLC6A6CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625878-B2 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | THE UNIVERSITY OF KANSAS (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1678211-A4 | SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRIN DERIVATIVES | UNIV KANSAS (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20060258537-A1 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | UNIVERSITY OF KANSAS | 2006-11-16 | — | — | US | disclosed |
| EP-1678211-A2 | SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRIN DERIVATIVES | THE UNIVERSITY OF KANSAS (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042584-A2 | SULFOALKYL ETHER-ALKYL ETHER CYCLODEXTRIN DERIVATIVES | THE UNIVERSITY OF KANSAS (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258537-A1 | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives | SELE, STS, EPCAM | APP 1864/4885LMNA 4070/4885SLC6A6 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.